This paper discusses the development of new downhole scale inhibitor products, and in particular the laboratory screening techniques used to select the best candidate for field testing. The minimum effective dosages for the products are determined in laboratory capillary tube tests. The product was then field tested at Kuparuk, the field for which it was designed. The performance was evaluated and compared to performance obtained from previous treatments with the incumbent product on a well by well basis, and the minimum effective dosages of the new product was determined from actual field data, thus enabling comparison between laboratory and field data.
Keywords: scale inhibitor, downhole, laboratory and field testing, minimum effective dosage, Kuparuk